Schönekaes K G, Prott F J, Micke O, Willich N, Wagner W
Paracelsus Strahlenklinik Osnabrück, Germany.
Anticancer Res. 1999 May-Jun;19(3B):2355-9.
Through adjuvant photon radiotherapy, it is possible to improve tumor control as well as avoid ultra radical surgery in patients with soft tissue sarcoma. Similar results have been obtained in cases of incomplete resected G1/G2 sarcoma after applying neutron radiotherapy. We compared the results of a group of patients with soft tissue sarcoma treated with those having received photon therapy (100 patients) or neutron therapy (61 patients). The median dose in the photon treated group was 60 Gy (range 45 to 65 Gy). The neutron therapy group received a median dose of 14.1 Gy (range 5.0 to 18.57 Gy). Patients treated with mixed-beam irradiation received an average dose of 36.5 Gy photon and 8.5 Gy neutrons. The 5-year survival rate of the photon group rated 43.1%. In the neutron group we found 42.5%, respectively. In both groups the results of surgical resection and grading were of high significance according to survival. 4% of the patients belonging to the photon group developed grade III/IV WHO side effects. In the neutron group side effects grade III/IV WHO were observed in 11% of the cases. Comparing treatment results of neutron and photon therapy we demonstrated that incompletely resected G1 and G2 tumor patients show greater benefit in the case of neutron radiotherapy.
通过辅助性光子放疗，对于软组织肉瘤患者而言，有可能改善肿瘤控制情况并避免进行超根治性手术。在应用中子放疗后，对于未完全切除的G1/G2肉瘤病例也取得了类似的结果。我们将一组接受软组织肉瘤治疗的患者的结果与接受光子治疗的患者（100例）或中子治疗的患者（61例）的结果进行了比较。光子治疗组的中位剂量为60 Gy（范围45至65 Gy）。中子治疗组接受的中位剂量为14.1 Gy（范围5.0至18.57 Gy）。接受混合束照射治疗的患者接受的平均光子剂量为36.5 Gy，中子剂量为8.5 Gy。光子组的5年生存率为43.1%。在中子组中，我们分别发现为42.5%。在两组中，手术切除结果和分级根据生存率具有高度显著性。光子组4%的患者出现了世界卫生组织III/IV级副作用。在中子组中，11%的病例观察到世界卫生组织III/IV级副作用。比较中子和光子治疗的结果，我们证明未完全切除的G1和G2肿瘤患者在中子放疗的情况下获益更大。
